{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:10:41Z","timestamp":1783422641474,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited evidence on the association between short-term changes in mineral and bone disorder parameters and survival in maintenance hemodialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the association between changing patterns of phosphorus, calcium and intact parathyroid hormone levels and all-cause mortality in hemodialysis patients with secondary hyperparathyroidism. Each parameter was divided into three categories (low [L], middle [M] and high [H]), and the changing patterns between two consecutive visits at 3-month intervals were categorized into nine groups (e.g., L-L and M-H). The middle category was defined as 4.0\u20137.0\u00a0mg\/dL for phosphorous, 8.5\u20139.5\u00a0mg\/dL for calcium and 200\u2013500\u00a0pg\/mL for intact parathyroid hormone. Adjusted incidence rates and rate ratios were analyzed by weighted Poisson regression models accounting for time-dependent exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For phosphorus, shifts from low\/high to middle category (L-M\/H-M) were associated with a lower mortality compared with the L-L and H\u2013H groups, whereas shifts from middle to low\/high category (M-L\/M-H) were associated with a higher mortality compared with the M-M group. For calcium, shifts from low\/middle to high category (L\u2013H\/M-H) were associated with a higher mortality compared with the L-L and M-M groups, whereas shifts from high to middle category (H-M) were associated with a lower mortality compared with the H\u2013H group. For intact parathyroid hormone, shifts from low to middle category (L-M) were associated with a lower mortality compared with the L-L group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Changes in the 3-month patterns of phosphorus and calcium toward the middle category were associated with lower mortality. Our study also suggests the importance of avoiding hypercalcemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-02088-x","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T09:02:56Z","timestamp":1602493376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism"],"prefix":"10.1186","volume":"21","author":[{"given":"Chihiro","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7717-8945","authenticated-orcid":false,"given":"Shinji","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Fukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihito","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"2088_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","volume":"44","author":"EW Young","year":"2004","unstructured":"Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34\u20138.","journal-title":"Am J Kidney Dis"},{"key":"2088_CR2","first-page":"2208","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am SocNephrol. 2004;15:2208\u201318.","journal-title":"J Am SocNephrol"},{"key":"2088_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.ki.5001514","volume":"70","author":"K Kalantar-Zadeh","year":"2006","unstructured":"Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771\u201380.","journal-title":"Kidney Int"},{"key":"2088_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519\u201330.","journal-title":"Am J Kidney Dis"},{"key":"2088_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1744-9987.12030","volume":"17","author":"M Taniguchi","year":"2013","unstructured":"Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. TherApher Dial. 2013;17:221\u20138.","journal-title":"TherApher Dial"},{"key":"2088_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1053\/j.ajkd.2013.08.011","volume":"63","author":"M Fukagawa","year":"2014","unstructured":"Fukagawa M, Kido R, Komaba H, Ohnishi Y, Yamaguchi T, Hasegawa T, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63:979\u201387.","journal-title":"Am J Kidney Dis"},{"key":"2088_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","volume":"30","author":"JL Fern\u00e1ndez-Mart\u00edn","year":"2015","unstructured":"Fern\u00e1ndez-Mart\u00edn JL, Mart\u00ednez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542\u201351.","journal-title":"Nephrol Dial Transplant"},{"key":"2088_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2015.12.001","volume":"89","author":"E Merle","year":"2016","unstructured":"Merle E, Roth H, London GM, Jean G, Hannedouche T, Bouchet JL, et al. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney Int. 2016;89:666\u201374.","journal-title":"Kidney Int"},{"key":"2088_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000444890","volume":"43","author":"M Soohoo","year":"2016","unstructured":"Soohoo M, Feng M, Obi Y, Streja E, Rhee CM, Lau WL, et al. Changes in markers of mineral and bone disorders and mortality in incident hemodialysis patients. Am J Nephrol. 2016;43:85\u201396.","journal-title":"Am J Nephrol"},{"key":"2088_CR10","doi-asserted-by":"publisher","first-page":"e0173831","DOI":"10.1371\/journal.pone.0173831","volume":"12","author":"R Villa-Bellosta","year":"2017","unstructured":"Villa-Bellosta R, Rodriguez-Osorio L, Mas S, Abadi Y, Rubert M, de la Piedra C, et al. A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. PLoS One. 2017;12:e0173831.","journal-title":"PLoS One"},{"issue":"7","key":"2088_CR11","first-page":"1","volume":"2017","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Working Group. KDIGO","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Working Group. KDIGO. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney IntSuppl. 2017;2017(7):1\u201359.","journal-title":"Kidney IntSuppl"},{"key":"2088_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1744-9987.2010.00906.x","volume":"15","author":"S Fukuhara","year":"2011","unstructured":"Fukuhara S, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, et al. Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D Patients: rationale and study design. TherApher Dial. 2011;15:169\u201375.","journal-title":"TherApher Dial"},{"key":"2088_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","volume":"12","author":"Guideline Working Group, Japanese Society for Dialysis Therapy","year":"2008","unstructured":"Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. TherApher Dial. 2008;12:514\u201325.","journal-title":"TherApher Dial"},{"key":"2088_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","volume":"4","author":"RB Payne","year":"1973","unstructured":"Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643\u20136.","journal-title":"Br Med J"},{"key":"2088_CR15","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates Publishers; 1988.","edition":"2"},{"key":"2088_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/1744-9987.12679","volume":"22","author":"H Fujii","year":"2018","unstructured":"Fujii H. Association between Parathyroid Hormone and Cardiovascular Disease. TherApher Dial. 2018;22:236\u201341. .","journal-title":"TherApher Dial"},{"key":"2088_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. TherApher Dial. 2013;17:247\u201388.","journal-title":"TherApher Dial"},{"key":"2088_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am SocNephrol. 2015;10:98\u2013109.","journal-title":"Clin J Am SocNephrol"},{"key":"2088_CR19","doi-asserted-by":"crossref","unstructured":"Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016;6:19612.","DOI":"10.1038\/srep19612"},{"key":"2088_CR20","doi-asserted-by":"crossref","unstructured":"Akizawa T, Kido R, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, et al. Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. Clin J Am SocNephrol. 2011;6:2280\u20138.","DOI":"10.2215\/CJN.11501210"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-02088-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T03:49:03Z","timestamp":1634010543000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02088-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2088"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02088-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16245\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16245\/v2","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the central ethics committee at Kobe University\u2019s School of Medicine. Informed consent was not mandatory according to the ethical guidelines for epidemiological research in Japan. Anonymized data was collected and analyzed. The study is registered at ClinicalTrials.gov (NCT00995163).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CK, SA, TN and MW are employees of Kyowa Kirin Co. ltd., (KKC). NF received grants from KKC. CM and YO do not have any conflicts of interest to declare. SF1 has acted as a scientific advisor for KKC. SF2 has acted as a scientific advisor for and has received grants from KKC. MF has received consulting fees from KKC and Ono Pharmaceutical; lecture fees from KKC, Bayer, Torii Pharmaceutical and Ono Pharmaceutical; and grants from KKC, Bayer and Ono Pharmaceutical. TA has received personal fees from KKC, Astellas Pharma, Bayer, Fuso Pharmaceutical, Japan Tobacco, Ono Pharmaceutical, NIPRO, Chugai Pharmaceutical, Kissei Pharmaceutical, Torii Pharmaceutical and Otsuka Pharmaceutical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}